Financials Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 10:59:51 2024-02-23 am EST 5-day change 1st Jan Change
478 DKK +1.10% Intraday chart for Zealand Pharma A/S -1.40% +28.08%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 2,532 8,472 8,766 6,271 10,366 29,701 29,701 -
Enterprise Value (EV) 1 1,372 7,092 7,638 5,364 9,712 27,949 26,501 26,071
P/E ratio 4.35 x -13.9 x -10 x -6.11 x -7.74 x -37.3 x 324 x 145 x
Yield - - - - - - - -
Capitalization / Revenue 66.6 x 205 x 24.8 x 21.4 x 99.7 x 85.6 x 21.3 x 25.1 x
EV / Revenue 36.1 x 172 x 21.6 x 18.3 x 93.4 x 80.6 x 19 x 22 x
EV / EBITDA 2.09 x -12.3 x -10.2 x -5.3 x -13.5 x -57.8 x 81.3 x -478 x
EV / FCF -2.95 x -16.5 x -10.7 x -4.35 x -10.2 x -57.4 x 94.7 x 85.6 x
FCF Yield -33.8% -6.07% -9.34% -23% -9.82% -1.74% 1.06% 1.17%
Price to Book 2.27 x 6.82 x 6.89 x 6.83 x 11.4 x 10.7 x 7.03 x 6.45 x
Nbr of stocks (in thousands) 30,723 35,990 39,735 43,216 51,470 62,135 62,135 -
Reference price 2 82.40 235.4 220.6 145.1 201.4 478.0 478.0 478.0
Announcement Date 3/7/19 3/11/20 3/11/21 3/10/22 3/1/23 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 38 41.3 353.3 292.6 104 346.8 1,397 1,185
EBITDA 1 656.9 -574.3 -749.7 -1,012 -719.2 -483.3 326 -54.57
EBIT 1 652.4 -587.9 -792.4 -1,052 -837.2 -516.2 481.2 225.5
Operating Margin 1,716.84% -1,423.49% -224.27% -359.7% -805.06% -148.84% 34.45% 19.03%
Earnings before Tax (EBT) 1 625.1 -576.7 -839.7 -1,027 -972 -604.2 388.2 207.3
Net income 1 581.3 -571.5 -846.7 -1,018 -1,202 -555.7 186.5 50.07
Net margin 1,529.69% -1,383.88% -239.65% -348.01% -1,156.05% -160.23% 13.35% 4.22%
EPS 2 18.94 -16.91 -22.07 -23.75 -26.02 -12.82 1.477 3.302
Free Cash Flow 1 -464.4 -430.5 -713.8 -1,234 -953.9 -486.9 279.8 304.5
FCF margin -1,222.21% -1,042.35% -202.02% -421.82% -917.35% -140.38% 20.03% 25.69%
FCF Conversion (EBITDA) - - - - - - 85.84% -
FCF Conversion (Net income) - - - - - - 150.05% 608.15%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/7/19 3/11/20 3/11/21 3/10/22 3/1/23 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3
Net sales 1 84.33 106.4 54.02 50.79 50.21 43.71 23.92 13.63 10.41 295.5 10.16 10.39 33.37 188.6
EBITDA - - - - - - - - - - - - - -
EBIT 1 -289.9 -211.8 -289.7 -343.4 -293.3 -162.1 -241 -168.7 -195.4 45.28 -228.9 -213.6 -190 -36.3
Operating Margin -343.81% -199.05% -536.42% -676.17% -584.12% -370.76% -1,007.18% -1,237.69% -1,877.25% 15.32% -2,251.84% -2,056.2% -569.21% -19.25%
Earnings before Tax (EBT) 1 -304.3 -195.7 -285.8 -210.4 -488.5 -153.7 -322.4 -195.3 -321 72.83 -235.6 - - -
Net income 1 -296.8 -198.9 -280.3 -222.8 -488.5 -148.3 -342.4 -193.6 -319.5 74.14 -233.6 - - -
Net margin -351.99% -186.91% -518.86% -438.79% -972.97% -339.35% -1,431.34% -1,420.84% -3,070.07% 25.09% -2,298.19% - - -
EPS 2 -6.870 -4.610 -6.490 -5.160 -11.04 -3.210 -6.740 -3.760 -5.500 1.230 -4.000 - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 8/12/21 11/11/21 3/10/22 5/12/22 8/11/22 11/10/22 3/1/23 5/11/23 8/17/23 11/9/23 - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 1,159 1,381 1,127 907 654 1,752 3,199 3,629
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -464 -430 -714 -1,234 -954 -487 280 305
ROE (net income / shareholders' equity) -54.1% -48.5% -68.5% -94.4% -138% -44% 49.9% 9.7%
ROA (Net income/ Total Assets) -45.2% -40.4% -50.4% -53.2% - - 24% 4.38%
Assets 1 -1,285 1,415 1,681 1,915 - - 776.7 1,143
Book Value Per Share 2 36.40 34.50 32.00 21.30 17.70 44.60 68.00 74.20
Cash Flow per Share 2 -15.00 -12.10 -17.90 -28.30 -20.40 -18.80 -8.000 18.70
Capex 1 4.04 21 25 22.1 11.7 17.2 9.78 11
Capex / Sales 10.63% 50.93% 7.09% 7.57% 11.26% 4.97% 0.7% 0.93%
Announcement Date 3/7/19 3/11/20 3/11/21 3/10/22 3/1/23 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
478 DKK
Average target price
459.2 DKK
Spread / Average Target
-3.94%
Consensus
1st Jan change Capi.
+28.08% 4 312 M $
+5.71% 111 B $
+11.72% 105 B $
+9.93% 24 182 M $
-10.96% 22 338 M $
-26.36% 21 352 M $
-6.59% 19 088 M $
-13.93% 16 173 M $
+1.84% 13 352 M $
+41.59% 12 772 M $
Bio Therapeutic Drugs
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer